Test of a new Lu-177-PSMA-based radiopharmaceutical at UCSF

[Tall_Allen]

I know many patients are interested in trying a Lu-177-PSMA-based radiopharmaceutical without being randomized. UCSF will be starting a dose-finding (non randomized) trial of a new Lu-177-PSMA-based radiopharmaceutical . It is for those with mCRPC who have tried docetaxel (but not Jevtana), and have failed Zytiga or Xtandi. Here are the details:

clinicaltrials.gov/ct2/show...

In NYC, Scott Tagawa at Weill Cornell is testing the J591 ligand. There are similar requirements.

clinicaltrials.gov/ct2/show...

He is also testing a new Ac-225-PSMA-J591 radiopharmaceutical:

clinicaltrials.gov/ct2/show...

[dadeb]

Happy to hear this. Wish we could have held on long enough - better to have skipped Radium 223 for this one.

[Tall_Allen in reply to dadeb]

The exclusion is only 90 days for Xofigo. It's benefit is known. If you had bone mets only, Xofigo is a better bet.

[dadeb in reply to Tall_Allen]

Good to know. Thanks! No looking back.

[CalBear74]

You were kind enough to identify three options: the question is can the same patient qualify for all three and if so which would you suggest he choose for efficacy over the other two?

[Tall_Allen in reply to CalBear74]

You can only do one because they preclude previous treatment by radiopharmaceuticals. These are ALL experimental and in Phase 1 trials, so I have no idea how safe or efficacious any of them are.

[CalBear74 in reply to Tall_Allen]

Assuming you could only do one, which one? And I guess you’re saying, we just don’t know yet which is the most efficacious? I was not suggesting that a patient could try and do more than one.

[Tall_Allen in reply to CalBear74]

J591 MAY be more specific (less toxic) than PSMA-617. Ac-225 is more effective a short-range cancer killing; Lu-177 has a wider scope. I know nothing about the ligand that UCSF is using. That's all I can say.